Literature DB >> 2004051

Angiotensin II levels in hypertensive and normotensive pregnancies.

M Hanssens1, M J Keirse, B Spitz, F A van Assche.   

Abstract

We measured circulating angiotension II by radioimmunoassay in women with pregnancy-induced hypertension (n = 54), and compared these values with those obtained in women with normal pregnancy (n = 18) and in non pregnant women (n = 20). Pregnant women had statistically significantly higher plasma angiotensin II [mean (SD): 41.3 (12.6) pg/ml] than non-pregnant women [29.2 (11.3) pg/ml; P less than 0.004]. Angiotensin II concentrations in women with pregnancy-induced hypertension [mean (SD): 31.7 (16.2) pg/ml] were, on average, 25% lower than in normal pregnancy (P less than 0.003) and resembled those obtained in non-pregnant women. The lowest angiotensin II levels were found in women with more severe forms of pregnancy-induced hypertension, such as proteinuric or superimposed pregnancy-induced hypertension. Review of the published studies on angiotensin II and our data suggest that the conflict among studies on angiotensin II levels in pregnancy-induced hypertension is largely due to the heterogeneity of the study populations in the various reports.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2004051     DOI: 10.1111/j.1471-0528.1991.tb13361.x

Source DB:  PubMed          Journal:  Br J Obstet Gynaecol        ISSN: 0306-5456


  20 in total

Review 1.  Regulation of sympathetic vasomotor activity by the hypothalamic paraventricular nucleus in normotensive and hypertensive states.

Authors:  Roger A Dampney; Lisete C Michelini; De-Pei Li; Hui-Lin Pan
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-08-10       Impact factor: 4.733

2.  GPCRs as potential therapeutic targets in preeclampsia.

Authors:  Jt McGuane; Kp Conrad
Journal:  Drug Discov Today Dis Models       Date:  2012-07-12

3.  New frontiers in heart hypertrophy during pregnancy.

Authors:  Jingyuan Li; Soban Umar; Marjan Amjedi; Andrea Iorga; Salil Sharma; Rangarajan D Nadadur; Vera Regitz-Zagrosek; Mansoureh Eghbali
Journal:  Am J Cardiovasc Dis       Date:  2012-07-25

4.  Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor.

Authors:  G Wallukat; V Homuth; T Fischer; C Lindschau; B Horstkamp; A Jüpner; E Baur; E Nissen; K Vetter; D Neichel; J W Dudenhausen; H Haller; F C Luft
Journal:  J Clin Invest       Date:  1999-04       Impact factor: 14.808

5.  Vitamin D supplementation reduces some AT1-AA-induced downstream targets implicated in preeclampsia including hypertension.

Authors:  Jessica L Faulkner; Lorena M Amaral; Denise C Cornelius; Mark W Cunningham; Tarek Ibrahim; Autumn Heep; Nathan Campbell; Nathan Usry; Kedra Wallace; Florian Herse; Ralf Dechend; Babbette LaMarca
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2016-11-30       Impact factor: 3.619

Review 6.  Renin-angiotensin system in pre-eclampsia: everything old is new again.

Authors:  Julia J Spaan; Mark A Brown
Journal:  Obstet Med       Date:  2012-12-06

7.  Nitric oxide synthase activity and expression are decreased in the paraventricular nucleus of pregnant rats.

Authors:  Cheryl M Heesch; Hong Zheng; C Michael Foley; Patrick J Mueller; Eileen M Hasser; Kaushik P Patel
Journal:  Brain Res       Date:  2008-11-19       Impact factor: 3.252

8.  Resistance artery adaptation to pregnancy counteracts the vasoconstricting influence of plasma from normal pregnant women.

Authors:  Odül A Amburgey; Shane A Reeves; Ira M Bernstein; Marilyn J Cipolla
Journal:  Reprod Sci       Date:  2009-09-18       Impact factor: 3.060

9.  Pregnancy upregulates angiotensin type 2 receptor expression and increases blood flow in uterine arteries of rats.

Authors:  Jay S Mishra; Kathirvel Gopalakrishnan; Sathish Kumar
Journal:  Biol Reprod       Date:  2018-11-01       Impact factor: 4.285

Review 10.  Pathophysiology of placentation abnormalities in pregnancy-induced hypertension.

Authors:  Mitsuko Furuya; Junji Ishida; Ichiro Aoki; Akiyoshi Fukamizu
Journal:  Vasc Health Risk Manag       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.